Intec Pharma Ltd. (NASDAQ:NTEC) and Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Intec Pharma Ltd.||N/A||0.00||43.54M||-1.40||0.00|
|Ligand Pharmaceuticals Incorporated||251.45M||10.68||143.32M||8.82||16.84|
Table 1 demonstrates Intec Pharma Ltd. and Ligand Pharmaceuticals Incorporated’s top-line revenue, earnings per share and valuation.
Table 2 provides us Intec Pharma Ltd. and Ligand Pharmaceuticals Incorporated’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Intec Pharma Ltd.||0.00%||0%||0%|
|Ligand Pharmaceuticals Incorporated||57.00%||32.3%||13.3%|
The next table highlights the delivered recommendations and ratings for Intec Pharma Ltd. and Ligand Pharmaceuticals Incorporated.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Intec Pharma Ltd.||0||0||0||0.00|
|Ligand Pharmaceuticals Incorporated||0||0||1||3.00|
Competitively Ligand Pharmaceuticals Incorporated has a consensus target price of $270, with potential upside of 113.71%.
Insider & Institutional Ownership
Intec Pharma Ltd. and Ligand Pharmaceuticals Incorporated has shares held by institutional investors as follows: 40.62% and 0%. About 11.4% of Intec Pharma Ltd.’s share are held by insiders. Competitively, Ligand Pharmaceuticals Incorporated has 2.1% of it’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Intec Pharma Ltd.||10.98%||30.61%||110.41%||72.58%||44.91%||49.13%|
|Ligand Pharmaceuticals Incorporated||-5.8%||-8.81%||-42.02%||-22.84%||12.91%||8.54%|
For the past year Intec Pharma Ltd. was more bullish than Ligand Pharmaceuticals Incorporated.
Ligand Pharmaceuticals Incorporated beats on 10 of the 11 factors Intec Pharma Ltd.
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The companyÂ’s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, oncology, allergy, anti-coagulant, depression, sun damage, blood disorders, and diabetes. The company is also involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated has alliances, licenses, and other business relationships with various pharmaceutical companies, including Novartis AG; Amgen, Inc.; Merck & Co., Inc.; Pfizer Inc.; Celgene; Gilead Sciences; Janssen Biotech, Inc.; Baxter International, Inc.; and Eli Lilly and Company. The company was founded in 1987 and is headquartered in San Diego, California.